Editor’s Note: This article originally appeared on Merck’s website.
KENILWORTH, N.J.–(BUSINESS WIRE)–AstraZeneca and Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) has approved LYNPARZA® (olaparib) tablets for use in patients with unresectable or recurrent BRCA-mutated (BRCAm), human epidermal growth factor receptor 2 (HER2)-negative breast cancer who have received prior chemotherapy. Patients are selected for therapy based on an approved companion diagnostic. Click here to continue>>
News from our partners
